ArticleCancer research2022

Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma.

Arun Kanakkanthara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.